Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interview: UK Initiative Bids To Boost Access To Cancer Clinical Trials

Fewer Than 50% Of Patients Told About Trials After Cancer Diagnosis

Executive Summary

The Christie cancer hospital in Manchester has linked up with Innovative Trials to try and get more minority and socially-deprived communities into clinical studies.

You may also be interested in...



Expanding The Tent: Improving Trial Participation Among Under-Represented Patient Populations

The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.

UCB And Analysts Believe Bimekizumab Will Be Super-Blockbuster

The psoriasis market is a tough one for bimekizumab to crack but UCB head of immunology Emmanuel Caeymaex believes the clinical package and investment in promotion will see the IL-17A and IL-17F inhibitor topple its rivals.

France's Erytech Closer To Realizing Market Ambitions With Eryaspase US Filing

It has taken almost two decades but it looks as though Erytech could get approval for eryaspase in the US in two indications next year – acute lymphoblastic leukemia and pancreatic cancer.

Topics

UsernamePublicRestriction

Register

SC141801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;